GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » Interest Coverage

Global Blood Therapeutics (Global Blood Therapeutics) Interest Coverage : 0 (At Loss) (As of Jun. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Global Blood Therapeutics's Operating Income for the three months ended in Jun. 2022 was $-75.7 Mil. Global Blood Therapeutics's Interest Expense for the three months ended in Jun. 2022 was $-8.4 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Global Blood Therapeutics's Interest Coverage or its related term are showing as below:


GBT's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 125.655
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Global Blood Therapeutics Interest Coverage Historical Data

The historical data trend for Global Blood Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Global Blood Therapeutics Interest Coverage Chart

Global Blood Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Interest Coverage
Get a 7-Day Free Trial Premium Member Only No Debt - - - -

Global Blood Therapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Global Blood Therapeutics's Interest Coverage

For the Biotechnology subindustry, Global Blood Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Global Blood Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Global Blood Therapeutics's Interest Coverage falls into.



Global Blood Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Global Blood Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2021 is calculated as

Here, for the fiscal year that ended in Dec. 2021, Global Blood Therapeutics's Interest Expense was $-15.5 Mil. Its Operating Income was $-287.7 Mil. And its Long-Term Debt & Capital Lease Obligation was $653.9 Mil.

Global Blood Therapeutics did not have earnings to cover the interest expense.

Global Blood Therapeutics's Interest Coverage for the quarter that ended in Jun. 2022 is calculated as

Here, for the three months ended in Jun. 2022, Global Blood Therapeutics's Interest Expense was $-8.4 Mil. Its Operating Income was $-75.7 Mil. And its Long-Term Debt & Capital Lease Obligation was $652.3 Mil.

Global Blood Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Global Blood Therapeutics  (NAS:GBT) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Global Blood Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Executives
Jeffrey S Farrow officer: Chief Financial Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo director ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik officer: Chief Human Resources Officer 6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink officer: Chief Human Resources Officer C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson director C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers officer: Chief Scientific Officer C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry director 176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love director, officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari officer: Chief Legal Officer 3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr. director C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080

Global Blood Therapeutics (Global Blood Therapeutics) Headlines

From GuruFocus

GBT Announces New Employment Inducement Grants

By PurpleRose PurpleRose 08-04-2022